Prior research has indicated that activating the TP53 pathway can heighten vulnerability to apoptosis, particularly in the context of Type 1 Diabetes Mellitus (T1DM) (Bernard et al., 2020; Lacroix et al., 2020; Punja et al., 2021). This evidence concerns the gene TP53 and diabetes mellitus.